quality adjusted life years

Summary

Summary: A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)

Top Publications

  1. ncbi The estimation of a preference-based measure of health from the SF-36
    John Brazier
    Sheffield Health Economics Group, School of Health and Related Research, University of Sheffield, UK
    J Health Econ 21:271-92. 2002
  2. ncbi The estimation of a preference-based measure of health from the SF-12
    John E Brazier
    Health Economics and Decision Science Group, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom
    Med Care 42:851-9. 2004
  3. ncbi [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]
    L M Lamers
    Instituut Beleid en Management Gezondheidszorg, Erasmus MC, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 149:1574-8. 2005
  4. ncbi A comparison of the EQ-5D and SF-6D across seven patient groups
    John Brazier
    Sheffield Health Economics Group, University of Sheffield, Sheffield, UK
    Health Econ 13:873-84. 2004
  5. ncbi Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions
    Elisabeth Fenwick
    Centre for Evaluation of Medicines, St Joseph s Hospital, Hamilton, Canada
    Health Econ 13:405-15. 2004
  6. ncbi Swedish population health-related quality of life results using the EQ-5D
    K Burstrom
    Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden
    Qual Life Res 10:621-35. 2001
  7. ncbi The 15D instrument of health-related quality of life: properties and applications
    H Sintonen
    Department of Public Health, University of Helsinki, Finland
    Ann Med 33:328-36. 2001
  8. pmc The Health Utilities Index (HUI): concepts, measurement properties and applications
    John Horsman
    Health Utilities Inc, Dundas, ON, Canada
    Health Qual Life Outcomes 1:54. 2003
  9. ncbi Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk
    Christopher J L Murray
    Evidence and Information for Policy, World Health Organization, 27, Geneva, Switzerland
    Lancet 361:717-25. 2003
  10. ncbi Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review
    Pirjo Räsänen
    Helsinki and Uusimaa Hospital Group, P O Box 100, 00029 HUS, Finland
    Int J Technol Assess Health Care 22:235-41. 2006

Detail Information

Publications337 found, 100 shown here

  1. ncbi The estimation of a preference-based measure of health from the SF-36
    John Brazier
    Sheffield Health Economics Group, School of Health and Related Research, University of Sheffield, UK
    J Health Econ 21:271-92. 2002
    ..These problems must be weighed against the rich descriptive ability of the SF-6D, and the potential application of these models to existing and future SF-36 data set...
  2. ncbi The estimation of a preference-based measure of health from the SF-12
    John E Brazier
    Health Economics and Decision Science Group, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom
    Med Care 42:851-9. 2004
    ..It has become widely used in clinical trials and routine outcome assessment because of its brevity and psychometric performance, but it cannot be used in economic evaluation in its current form...
  3. ncbi [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]
    L M Lamers
    Instituut Beleid en Management Gezondheidszorg, Erasmus MC, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 149:1574-8. 2005
    ..To value EQ-5D health states by a general Dutch public. EQ-5D is a standardised questionnaire that is used to calculate quality-adjusted life-years for cost-utility analysis...
  4. ncbi A comparison of the EQ-5D and SF-6D across seven patient groups
    John Brazier
    Sheffield Health Economics Group, University of Sheffield, Sheffield, UK
    Health Econ 13:873-84. 2004
    ..Further research is required to fully understand the respective roles of the descriptive systems and the valuation methods and to examine the implications for estimates of the impact of health care interventions...
  5. ncbi Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions
    Elisabeth Fenwick
    Centre for Evaluation of Medicines, St Joseph s Hospital, Hamilton, Canada
    Health Econ 13:405-15. 2004
    ..The aim of the paper is to serve as a reference tool to accompany the increased use of CEACs within major medical journals...
  6. ncbi Swedish population health-related quality of life results using the EQ-5D
    K Burstrom
    Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden
    Qual Life Res 10:621-35. 2001
    ..0001). In conclusion, our results show that the HRQoL varies greatly between socio-economic and disease groups. Furthermore, after controlling for age, sex and disease, HRQoL is lower in manual than in non-manual groups...
  7. ncbi The 15D instrument of health-related quality of life: properties and applications
    H Sintonen
    Department of Public Health, University of Helsinki, Finland
    Ann Med 33:328-36. 2001
    ..The instrument is recommended by the Washington Panel and is available in several languages for clinical economic evaluation and population studies...
  8. pmc The Health Utilities Index (HUI): concepts, measurement properties and applications
    John Horsman
    Health Utilities Inc, Dundas, ON, Canada
    Health Qual Life Outcomes 1:54. 2003
    ..The widespread use of HUI facilitates the interpretation of results and permits comparisons of disease and treatment outcomes, and comparisons of long-term sequelae at the local, national and international levels...
  9. ncbi Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk
    Christopher J L Murray
    Evidence and Information for Policy, World Health Organization, 27, Geneva, Switzerland
    Lancet 361:717-25. 2003
    ....
  10. ncbi Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review
    Pirjo Räsänen
    Helsinki and Uusimaa Hospital Group, P O Box 100, 00029 HUS, Finland
    Int J Technol Assess Health Care 22:235-41. 2006
    ..Furthermore, the aims were to characterize studies with regard to medical specialty, intervention studied, results obtained, quality, country of origin, QALY gain observed, and interpretation of results regarding cost-effectiveness...
  11. ncbi Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis
    Nancy Devlin
    City Health Economics Centre, Department of Economics, City University, UK
    Health Econ 13:437-52. 2004
    ..The results suggest a threshold somewhat higher than NICEs stated 'range of acceptable cost effectiveness' of pound 20,000-30,000 British pounds per QALY--although the exact meaning of a 'range' in this context remains unclear...
  12. ncbi Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis
    Charles H King
    Center for Global Health and Diseases, Wolstein 4126, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106 7286, USA
    Lancet 365:1561-9. 2005
    ..To develop an evidenced-based reassessment of schistosomiasis-related disability, we did a systematic review of data on disability-associated outcomes for all forms of schistosomiasis...
  13. ncbi What is the price of life and why doesn't it increase at the rate of inflation?
    Peter A Ubel
    University of Michigan Health Systems 300 N Ingalls, Room 7C27 Ann Arbor, MI 48109 0429, USA
    Arch Intern Med 163:1637-41. 2003
  14. ncbi Estimating an EQ-5D population value set: the case of Japan
    Aki Tsuchiya
    School of Health and Related Research, University of Sheffield, UK
    Health Econ 11:341-53. 2002
    ..001 for 8 of 12 coefficients; F-test). Thirdly, using alternative models, the predictions are improved so that the local Japanese value set achieves MAE in the order of 0.01...
  15. ncbi Multiattribute and single-attribute utility functions for the health utilities index mark 3 system
    David Feeny
    Institute of Health Economics Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
    Med Care 40:113-28. 2002
    ..HUI3 consists of eight attributes (or dimensions) of health status: vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain with 5 or 6 levels per attribute, varying from highly impaired to normal...
  16. ncbi Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility
    Andrea Manca
    Centre for Health Economics, University of York, UK
    Health Econ 14:487-96. 2005
    ....
  17. pmc Bias in published cost effectiveness studies: systematic review
    Chaim M Bell
    St Michael s Hospital, Toronto, Ontario, Canada M5B 1W8
    BMJ 332:699-703. 2006
    ....
  18. ncbi The cost effectiveness of combination antiretroviral therapy for HIV disease
    K A Freedberg
    Division of General Internal Medicine and the Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 344:824-31. 2001
    ..We estimated the clinical benefits and cost effectiveness of three-drug antiretroviral regimens...
  19. ncbi A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions
    - Nan Luo
    Centre for Health Services Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    Med Decis Making 27:321-6. 2007
    ..Empirical studies are needed to examine whether these 2 EQ-5D scoring functions would lead to different conclusions in cost-utility analyses...
  20. pmc The global burden of injuries
    E G Krug
    World Health Organization, Geneva, Switzerland
    Am J Public Health 90:523-6. 2000
    ....
  21. ncbi Resource allocation, social values and the QALY: a review of the debate and empirical evidence
    David L B Schwappach
    Department of Health Policy and Management, Faculty of Medicine, University Witten Herdecke, Witten, Germany
    Health Expect 5:210-22. 2002
    ..Recent approaches that aim to capture public preferences more comprehensively and to better reflect the value attributed to different health-care programmes in economic evaluation methods are outlined briefly...
  22. ncbi The burden of major depression avoidable by longer-term treatment strategies
    Theo Vos
    Department of Human Services, Melbourne, Australia School of Population Health, University of Queensland, Herston, Australia
    Arch Gen Psychiatry 61:1097-103. 2004
    ..Major depression is the largest single cause of nonfatal disease burden in Australia. Effective drug and psychological treatments exist, yet are underused...
  23. ncbi Representing uncertainty: the role of cost-effectiveness acceptability curves
    E Fenwick
    Centre for Health Economics, University of York, York, UK
    Health Econ 10:779-87. 2001
    ..We hope that as a result we can encourage the greater use of these techniques...
  24. ncbi Are QALYs based on time trade-off comparable?--A systematic review of TTO methodologies
    Trude Arnesen
    National Institute of Public Health, Oslo, Norway
    Health Econ 14:39-53. 2005
    ..This review of the TTO elicited on own behalf, shows that limiting cost-utility analysis to include only quality life weights from one method and one perspective is not enough to ensure that QALYs are comparable...
  25. ncbi Estimating the global disease burden due to ultraviolet radiation exposure
    Robyn M Lucas
    National Centre for Epidemiology and Population Health, The Australian National University, Australia
    Int J Epidemiol 37:654-67. 2008
    ..We report here the global disease burden due to ultraviolet radiation (UVR) exposure...
  26. ncbi Willingness to pay for a quality-adjusted life year: in search of a standard
    R A Hirth
    Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor 48109 2029, USA
    Med Decis Making 20:332-42. 2000
    ..With the exception of HK, these far exceed the "rules of thumb" that are frequently used to determine whether an intervention produces an acceptable increase in health benefits in exchange for incremental expenditures...
  27. pmc Global socioeconomic impact of cystic echinococcosis
    Christine M Budke
    University of Zurich, Zurich, Switzerland
    Emerg Infect Dis 12:296-303. 2006
    ..This initial valuation demonstrates the necessity for increased monitoring and global control of CE...
  28. pmc The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting
    J J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Program in Health Decision Science, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, USA
    Br J Cancer 97:1322-8. 2007
    ..In a resource-constrained setting such as Brazil, our results support that the first priority in reducing cervical cancer mortality should be to vaccinate pre-adolescent girls...
  29. ncbi The cost-utility of screening for depression in primary care
    M Valenstein
    Health Services Research and Development, Department of Veterans Affairs Medical Center, Box 130170, Ann Arbor, MI 48113-0170, USA
    Ann Intern Med 134:345-60. 2001
    ..CONCLUSIONS: Annual and periodic screening for depression cost more than $50 000/QALY, but one-time screening is cost-effective. The cost-effectiveness of screening is likely to improve if treatment becomes more effective...
  30. ncbi Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction
    G D Sanders
    Center for Primary Care and Outcomes Research, 179 Encina Commons, Stanford University, Stanford, CA 94305 6019, USA
    Ann Intern Med 135:870-83. 2001
    ..Clinical trials have shown that implantable cardioverter defibrillators (ICDs) improve survival in patients with sustained ventricular arrhythmias...
  31. ncbi Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health
    Ingolf Griebsch
    MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Whiteladies Road, Bristol BS8 2PR, United Kingdom
    Pediatrics 115:e600-14. 2005
    ....
  32. ncbi Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study
    Talitha L Feenstra
    National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    Value Health 8:178-90. 2005
    ....
  33. ncbi Adaptation and scale of reference bias in self-assessments of quality of life
    W Groot
    Department of Health Sciences, Maastricht University, Netherlands
    J Health Econ 19:403-20. 2000
    ..It is found that the scale of reference of the subjective health measure changes with age. Accounting for adaptation and scale of reference bias lowers most of the QALY weights for health problems and disabilities...
  34. ncbi Mapping the SF-12 to the HUI3 and VAS in a managed care population
    Nishan Sengupta
    Center for Pharmaceutical Appraisal and Outcomes Research, Abbott Lab, Lake Bluff, Illinois, USA
    Med Care 42:927-37. 2004
    ..Transforming generic health-related quality of life (HRQOL) instruments to a summary utility index is useful for deriving quality-adjusted life years (QALY) in any cost/QALY analysis...
  35. ncbi Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report
    Scott Ramsey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Value Health 8:521-33. 2005
    ..Its goal was to develop a guidance document for designing, conducting, and reporting cost-effectiveness analyses conducted as a part of clinical trials...
  36. pmc Measuring the burden of neglected tropical diseases: the global burden of disease framework
    Colin D Mathers
    Information, Evidence and Research Cluster, World Health Organization, Geneva, Switzerland
    PLoS Negl Trop Dis 1:e114. 2007
    ..3% of the global burden of disease and injuries. Further research is currently underway to revise and update these estimates...
  37. ncbi Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand
    Yot Teerawattananon
    Ministry of Public Health, Nonthaburi, Thailand
    Value Health 10:61-72. 2007
    ..To examine the value for money of including peritoneal dialysis (PD) or hemodialysis (HD) into the universal health insurance scheme of Thailand...
  38. pmc The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance
    William H Herman
    University of Michigan Health System, Ann Arbor, Michigan, USA
    Ann Intern Med 142:323-32. 2005
    ..The Diabetes Prevention Program (DPP) demonstrated that interventions can delay or prevent the development of type 2 diabetes...
  39. ncbi Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions
    Jack Dowie
    Public Health and Policy Department, London School of Hygiene and Tropical Medicine, Kepper Street, London WC1E 7HT, UK
    Health Econ 11:1-8. 2002
    ..But it has a supplementary basis in rejection of the widespread (but unjustifiable) belief that CSMs are more "sensitive" or "responsive" than GENs and hence can detect "small but important changes" that GENs always or often miss...
  40. ncbi The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison
    Rianne Oostenbrink
    Sophia Children s Hospital Rotterdam, Room Sp 1545, Dr Molewaterplein 60, The Netherlands
    J Clin Epidemiol 55:791-9. 2002
    ..This may be different in a cost-utility analysis of therapeutic strategies. Hence, sensitivity analysis to quality weights is recommended...
  41. pmc Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis
    Catherine L Keating
    1Centre for Obesity Research and Education, Monash University, Melbourne, Australia
    Diabetes Care 32:567-74. 2009
    ..To estimate the cost-effectiveness of surgically induced weight loss relative to conventional therapy for the management of recently diagnosed type 2 diabetes in class I/II obese patients...
  42. pmc Review of NICE's recommendations, 1999-2005
    James Raftery
    Wessex Institute of Health Research and Development, University of Southampton, Southampton SO16 7PX
    BMJ 332:1266-8. 2006
  43. ncbi Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis
    Nick Bansback
    St Paul s Hospital, Vancouver, British Columbia, Canada
    Arthritis Rheum 57:963-71. 2007
    ....
  44. ncbi Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group
    Mandy Van Den Brink
    Department of Medical Decision Making, J10 S, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 22:244-53. 2004
    ..To compare the societal costs and the (quality-adjusted) life expectancy of patients with rectal cancer undergoing total mesorectal excision (TME) with or without short-term preoperative radiotherapy (5 x 5 Gy)...
  45. ncbi Measuring health in a vacuum: examining the disability weight of the DALY
    Daniel D Reidpath
    UNICEF India Country Office in Delhi
    Health Policy Plan 18:351-6. 2003
    ..There is, consequently, a loss of information on possible non-clinical points of intervention. Disaggregated estimates of the burden of disease such as those in the World Health Report 2000 should be interpreted with caution...
  46. ncbi Selecting a decision model for economic evaluation: a case study and review
    J Karnon
    Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UK
    Health Care Manag Sci 1:133-40. 1998
    ..This section aims to illustrate the areas in which the alternative modelling methods may be most appropriately employed...
  47. pmc The burden of disease and injury in Australia
    C D Mathers
    Health Division, Australian Institute of Health and Welfare, Canberra ACT
    Bull World Health Organ 79:1076-84. 2001
    ..The lessons learnt from the ABD study are discussed, together with methodological issues that require further attention...
  48. ncbi The relationship between descriptive and valuational quality-of-life measures in patients with intermittent claudication
    J L Bosch
    Department of Health Sciences, University of Groningen, The Netherlands
    Med Decis Making 16:217-25. 1996
    ..These results suggest that answers to descriptive health-status questions cannot reliably predict standard-gamble utilities or time-tradeoff values...
  49. ncbi An experimental test of a theoretical foundation for rating-scale valuations
    H Bleichrodt
    Department of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
    Med Decis Making 17:208-16. 1997
    ....
  50. ncbi Cost effectiveness of herpes zoster vaccine in Canada
    Mehdi Najafzadeh
    Collaboration for Outcomes Research and Evaluation CORE, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Pharmacoeconomics 27:991-1004. 2009
    ..The lifetime risk of HZ is about 20-30% and the incidence increases with age. The protective effect of the HZ vaccine has been shown in a large clinical trial; however, the effectiveness of the vaccine decreased with age of vaccination...
  51. ncbi Measurement of health preferences among patients with tuberculous infection and disease
    Marie Josée Dion
    Respiratory Epidemiology Unit, McGill University, Montreal, Quebec, Canada
    Med Decis Making 22:S102-14. 2002
    ..Administration of the visual analogue scale and standard gamble instruments appeared reliable in a selected group of tuberculosis patients. Major barriers to recruitment were language and mobility in this largely foreign-born population...
  52. ncbi A meta-analysis of utility estimates for HIV/AIDS
    Tammy O Tengs
    Health Priorities Research Group, School of Social Ecology, University of California, Irvine 92697 7075, USA
    Med Decis Making 22:475-81. 2002
    ..The pooled utilities reported here should be of great use to researchers performing cost-utility analyses of interventions for HIV/AIDS...
  53. pmc Cost effectiveness of diagnostic strategies for patients with acute, undifferentiated chest pain
    S Goodacre
    School of Health and Related Research, Sheffield University, UK
    Emerg Med J 20:429-33. 2003
    ..This paper aimed to estimate the relative cost effectiveness of these strategies...
  54. ncbi Model to assess the cost-effectiveness of new treatments for depression
    Patrik Sobocki
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet and European Health Economics AB, Stockholm, Sweden
    Int J Technol Assess Health Care 22:469-77. 2006
    ..The objective of this study was to develop a model to assess the cost-effectiveness of a new treatment for patients with depression...
  55. ncbi Validity and feasibility of the use of condition-specific outcome measures in economic evaluation
    Elly A Stolk
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Qual Life Res 12:363-71. 2003
    ..An alternative strategy is to attribute utility scores to health states of a condition-specific outcomes measure (CSOM). We explored the validity and feasibility of this strategy...
  56. pmc Economic evaluation of human papillomavirus vaccination in the United Kingdom
    Mark Jit
    Modelling and Economics Unit, Centre for Infections, Health Protection Agency, London NW9 6BT
    BMJ 337:a769. 2008
    ..To assess the cost effectiveness of routine vaccination of 12 year old schoolgirls against human papillomavirus infection in the United Kingdom...
  57. ncbi Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States
    Colin W Shepard
    Division of Viral Hepatitis, National Center for Infectious Diseases, US Centers for Disease Control and Prevention, 1600 Clifton Rd, MS G37, Atlanta, GA 30333, USA
    Pediatrics 115:1220-32. 2005
    ..The US Food and Drug Administration approved a meningococcal conjugate A/C/Y/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years...
  58. pmc Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care
    David Wonderling
    Health Services Research Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 328:747. 2004
    ..To evaluate the cost effectiveness of acupuncture in the management of chronic headache...
  59. ncbi Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis
    C J McCarthy
    Centre for Rehabilitation Science, University of Manchester, Manchester Royal Infirmary, UK
    Health Technol Assess 8:iii-iv, 1-61. 2004
    ..To establish the relative effectiveness and cost of providing a home-based exercise programme versus home-based exercise supplemented with an 8-week class-based exercise programme...
  60. ncbi A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee
    Paul Grootendorst
    Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 34:534-42. 2007
    ....
  61. ncbi When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Richard H Chapman
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Health Econ 13:429-36. 2004
    ....
  62. ncbi Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal
    Christopher Evans
    Mapi Values, 15 Court Square, Suite 620, Boston, MA 02108, USA
    Health Care Manag Sci 7:43-9. 2004
    ..Further, the inconsistent application of benchmarks, and differences in the calculation of a value of a statistical life, will lead to an inefficient allocation of health care resources...
  63. ncbi Double discounting of QALYs
    Linda D MacKeigan
    Faculty of Pharmacy, University of Toronto, Toronto, Canada
    Health Econ 12:165-9. 2003
    ..Adjusting TTO-based quality weights prior to external discounting reduced the discrepancy only slightly. Since time preference effects may vary with health state context, the double discounting effect needs further investigation...
  64. ncbi The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
    Andrew J Palmer
    CORE Center for Outcomes Research, Basel, Switzerland
    Curr Med Res Opin 20:S5-26. 2004
    ..The development of complications, life expectancy, quality-adjusted life expectancy and total costs within populations can be calculated...
  65. pmc Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ
    D L Scott
    Department of Rheumatology, King s College London School of Medicine, Weston Education Centre, King s College, Cutcombe Road, London SE5 9RS, UK
    Ann Rheum Dis 66:1534-7. 2007
    ..Consequently linear regression methods have been used to transform Health Assessment Questionnaire (HAQ) scores into utility measures. The authors examined whether this is justified...
  66. ncbi An experimental test of question framing in health state utility assessment
    K Blumenschein
    College of Pharmacy, University of Kentucky, Lexington, USA
    Health Policy 45:187-93. 1998
    ..The null hypothesis of no difference between the loss and gain versions is rejected for the standard gamble method, but not for the time trade-off method...
  67. ncbi Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps
    P Vold Pepper
    Department of General Internal Medicine, Naval Medical Center San Diego, San Diego, CA 92134 5000, USA
    Clin Infect Dis 30:157-64. 2000
    ..On the basis of these results, the military should consider expanding current guidelines to include pneumococcal vaccine immunization for all active-duty members of the military...
  68. ncbi A comparison of three measures: the time trade-off technique, global health-related quality of life and the SF-36 in dialysis patients
    Y Maor
    The Center for the Study of Clinical Reasoning, The Gertner Institute for Epidemiology and Health Policy Research, Sackler School of Medicine, Tel Aviv University, Sheba Medical Center, 52621, Tel Hashomer, Israel
    J Clin Epidemiol 54:565-70. 2001
    ..This confirmed our suspicion that a qualitative difference exists between TTO and descriptive quality of life tools. The TTO content could not be explained by the variables that entail the content of HRQL instruments...
  69. ncbi The cost-effectiveness of hearing-aid fitting in the Netherlands
    Manuela A Joore
    Department of Clinical Epidemiology and Medical Technology Assessment, University Hospital Maastricht, The Netherlands
    Arch Otolaryngol Head Neck Surg 129:297-304. 2003
    ..To determine the cost-effectiveness of hearing-aid fitting...
  70. ncbi A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Qual Life Res 11:37-45. 2002
    ..We explore alternative options to customize the graphic representation for other data sets drawn from several NCCTG clinical trials...
  71. ncbi Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders
    C Issakidis
    School of Psychiatry, University of New South Wales, WHO Collaborating Centre for Evidence and Health Policy in Mental Health, St Vincent s Hospital, Sydney, NSW, Australia
    Psychol Med 34:19-35. 2004
    ..This paper reports on the findings for the anxiety disorders (panic disorder/agoraphobia, social phobia, generalized anxiety disorder, post-traumatic stress disorder and obsessive compulsive disorder)...
  72. ncbi Home care as an option in worsening chronic heart failure -- a pilot study to evaluate feasibility, quality adjusted life years and cost-effectiveness
    Harshida Patel
    Institute of Health and Care Sciences, Sahlgrenska Academy, Sweden
    Eur J Heart Fail 10:675-81. 2008
    ..Worsening chronic heart failure (CHF) is largely characterized by frequent hospital admissions and the need for specialist care...
  73. pmc A randomised controlled trial of acupuncture care for persistent low back pain: cost effectiveness analysis
    J Ratcliffe
    School of Health and Related Research, University of Sheffield
    BMJ 333:626. 2006
    ..To evaluate the cost effectiveness of acupuncture in the management of persistent non-specific low back pain...
  74. ncbi Limitations of the methods used for calculating quality-adjusted life-year values
    Gerard Duru
    CNRS French National Center for Scientific Research, Universite Claude Bernard Lyon I, bâtiment 101, 43 Boulevard du 11 Novembre 1918, 69622 Villeurbanne, France
    Pharmacoeconomics 20:463-73. 2002
    ..To test the validity of the techniques used to calculate quality-adjusted life-year (QALY) values based on utility functions, using a real population dataset...
  75. ncbi Efficiency, equity, and budgetary policies: informing decisions using mathematical programming
    David M Epstein
    Centre for Health Economics, University of York, York, UK
    Med Decis Making 27:128-37. 2007
    ..They apply this framework of analysis to a realistic and policy-relevant problem...
  76. ncbi Use of disability adjusted life years in the estimation of the disease burden of echinococcosis for a high endemic region of the Tibetan plateau
    Christine M Budke
    Institute for Parasitology, University of Zurich, Winterthurerstrasse 26a, CH 8057 Zurich, Switzerland
    Am J Trop Med Hyg 71:56-64. 2004
    ..This study has clearly shown that the impact of DALYs lost due to echinococcosis, in terms of medical treatment costs, lost income, and physical and social suffering, is likely to be substantial in this highly endemic region of China...
  77. ncbi Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries
    Jan B Oostenbrink
    Institute for Medical Technology Assessment, Erasmus MC Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Value Health 8:32-46. 2005
    ..In this article we compare The Netherlands and Canada...
  78. pmc Health and economic implications of HPV vaccination in the United States
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 359:821-32. 2008
    ..The cost-effectiveness of prophylactic vaccination against human papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for guidelines for immunization in the United States...
  79. ncbi The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D
    Samuli I Saarni
    Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland
    Qual Life Res 15:1403-14. 2006
    ..We investigated the impact of major chronic conditions on HRQoL using 15D and EQ-5D in a representative sample of Finns...
  80. pmc Cost-effectiveness of human papillomavirus vaccination in the United States
    Harrell W Chesson
    Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Emerg Infect Dis 14:244-51. 2008
    ..This consistency is reassuring because models of varying complexity will be essential tools for policy makers in the development of optimal HPV vaccination strategies...
  81. ncbi Assessing the cost-effectiveness of HAART for adults with HIV in England
    A H Miners
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    HIV Med 2:52-8. 2001
    ..To assess the cost-effectiveness of highly active antiretroviral therapy (HAART) compared with two nucleoside reverse transcriptase inhibitors (NRTIs) for HIV infected individuals...
  82. pmc Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination
    Jeremy D Goldhaber-Fiebert
    Doctoral Program in Health Policy, Decision Science Concentration, Harvard University, Cambridge, MA, USA
    J Natl Cancer Inst 100:308-20. 2008
    ....
  83. ncbi Benefits and costs of using HPV testing to screen for cervical cancer
    Jeanne S Mandelblatt
    Lombardi Cancer Center, 2233 Wisconsin Ave NW, Suite 317, Washington, DC 20007
    JAMA 287:2372-81. 2002
    ..Despite quality assurance standards, Papanicolaou (Pap) test characteristics remain less than optimal...
  84. ncbi Not all "quality-adjusted life years" are equal
    C A Marra
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Epidemiol 60:616-24. 2007
    ..There is evidence that utility elicitation methods used in the calculation of quality-adjusted life years (QALYs) yield different results. It is not clear how these differences impact economic evaluations...
  85. pmc Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    A Simon Pickard
    Center for Pharmacoeconomic Research, College of Pharmacy, Room 164, 833 S, Wood St MC886, University of Illinois at Chicago, 60612, USA
    Health Qual Life Outcomes 3:11. 2005
    ..The purpose of this study was to illustrate how decision-making could be affected by the choice of preference-based algorithms for the SF-36 and SF-12, and provide some guidance on selecting an appropriate algorithm...
  86. ncbi Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996)
    B George
    Centre for Policy and Practice, University of London School of Pharmacy, Tower Hamlets PCG and Barts and the London NHS Trust, London, UK
    Pharmacoeconomics 19:1103-9. 2001
    ..In addition, we explored whether the past decisions by the PBAC revealed a threshold incremental cost-effectiveness ratio beyond which the PBAC is not prepared to recommend reimbursement of a drug...
  87. pmc NICE's cost effectiveness threshold
    John Appleby
    BMJ 335:358-9. 2007
  88. ncbi Sensitivity and perspective in the valuation of health status: whose values count?
    G A De Wit
    Center for Health Policy and Law, Erasmus University, Rotterdam, The Netherlands
    Health Econ 9:109-26. 2000
    ..The implications of this finding for valuation research and policy-making are discussed...
  89. pmc The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers
    Elbert S Huang
    The University of Chicago, 5841 S, Maryland Avenue, MC 2007, Chicago, IL 60637, USA
    Health Serv Res 42:2174-93; discussion 2294-323. 2007
    ..To estimate the incremental cost-effectiveness of improving diabetes care with the Health Disparities Collaborative (HDC), a national collaborative quality improvement (QI) program conducted in community health centers (HCs)...
  90. ncbi Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial
    M Schoenbaum
    RAND, 1200 S Hayes St, Arlington, VA 22202, USA
    JAMA 286:1325-30. 2001
    ..Depression is a leading cause of disability worldwide, but treatment rates in primary care are low...
  91. ncbi A comparison of patient and social tariff values derived from the time trade-off method
    N Zethraeus
    Department of Economics, Stockholm School of Economics, Stockholm, Sweden
    Health Econ 8:541-5. 1999
    ..There was a close correspondence between social-tariff values and patient TTO values for relatively good health states, whereas the social tariff TTO values were lower than the patient TTO values for severe health states...
  92. ncbi Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen UniversityInstitute for Drug Exploration, Groningen, The Netherlands
    Clin Ther 28:432-44. 2006
    ....
  93. ncbi Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate
    Lee R Mobley
    Division for Health Services and Social Policy Research, RTI International Research Triangle Institute, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Med Decis Making 26:194-206. 2006
    ..The authors conclude that screening and treating with alendronate are more cost-effective than screening and treating with raloxifene or HRT. Relative to an NST strategy, alendronate has a fairly good cost-effectiveness ratio...
  94. ncbi The NICE cost-effectiveness threshold: what it is and what that means
    Christopher McCabe
    Academic Unit of Health Economics and NICE Decision Support Unit, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Pharmacoeconomics 26:733-44. 2008
    ..The development of a programme of disinvestment guidance would enable NICE and the NHS to be more confident that the net health benefit of the Technology Appraisal Programme is positive...
  95. ncbi Calculating QALYs, comparing QALY and DALY calculations
    Franco Sassi
    Department of Social Policy, The London School of Economics and Political Science, London, UK
    Health Policy Plan 21:402-8. 2006
    ..Understanding similarities and differences between QALYs and DALYs is important to researchers and policy makers, for a sound interpretation of the evidence on the outcomes of health interventions...
  96. ncbi Money for health: the equivalent variation of cardiovascular diseases
    Wim Groot
    Department of Economics, University of Amsterdam, The Netherlands
    Health Econ 13:859-72. 2004
    ..The cost-benefit analysis shows that for most interventions the value of the health benefits exceeds the costs. Heart transplants seem to be too costly and only beneficial if patients are young...
  97. ncbi The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature
    Susan L Dennett
    Strategic Health Outcomes, Carmel, IN 46033, USA
    Value Health 11:478-86. 2008
    ..Selecting utility values for incorporation into cost-utility analyses (CUAs) of T2DM therapies is difficult because of variations in methodologies to elicit utilities and other study limitations...
  98. ncbi Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection
    Miguel R Arguedas
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Am J Gastroenterol 99:1023-8. 2004
    ..We have incorporated these new data into a revised Markov model to examine the cost-effectiveness of surgical versus medical therapy in patients with severe reflux esophagitis...
  99. ncbi Burden of diseases in Amhara region, Ethiopia
    Mesganaw Fantahun
    Department of Community Health, Faculty of Medicine, Addis Ababa University, P O Box 9086, Addis Ababa, Ethiopia
    Ethiop Med J 42:165-72. 2004
    ..The findings of this study can be used to design appropriate strategies and use health resources efficiently...
  100. ncbi Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom
    J Karnon
    School of Health and Related Research, University of Sheffield, UK
    Curr Med Res Opin 24:1609-21. 2008
    ..The perspective adopted was that of the National Health Service in the UK...
  101. ncbi Responsiveness of generic health-related quality of life measures in stroke
    A Simon Pickard
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60610, USA
    Qual Life Res 14:207-19. 2005
    ..To compare five preference-based generic measures of health-related quality of life (HRQOL) in terms of change scores, correlations among change scores, responsiveness, and quality adjusted life-years (QALYs) gained...

Research Grants64

  1. ANALYSIS OF TRYPANOSOME MRNA SYNTHESIS BY GENE TRANSFER
    Vivian Bellofatto; Fiscal Year: 2010
    ..The goal of our biomedical work is to define unique features of trypanosome biology and then to exploit these traits for the design of anti-parasitic chemotherapies. ..
  2. Validation of a functional MRI-based reward processing task as a non-invasive too
    MARY LOUISE PHILLIPS; Fiscal Year: 2010
    ....
  3. Breast Carcinoma in situ: Predicting Risk and Outcomes
    Amy Trentham-Dietz; Fiscal Year: 2013
    ..The long-term goal of this project is to reduce the public health impact of BCIS by quantifying both contextual and personal risk factors for the development of BCIS and the recurrence of breast cancer after a BCIS diagnosis. ..
  4. Neurologic manifestations of cerebrovascular disease in Da Nang, Viet Nam
    Annette L Fitzpatrick; Fiscal Year: 2010
    ....
  5. Human serum carbonyl proteome in cardiovascular diseases
    Nisha Jain Garg; Fiscal Year: 2010
    ..These studies will yield potential targets for the development of new drug therapies. ..
  6. Musculoskeletal Disorders and Health Behaviors among US Workers
    ALBERTO JUAN CABAN MARTINEZ; Fiscal Year: 2010
    ..3. Estimate the health-related quality of life effects of having musculoskeletal disorders using Quality Adjusted Life Years (QALYS) by occupation and NORA Industry sector...
  7. The Living Well Project: Early Palliative Care and MI for persons with AIDS
    Tammie E Quest; Fiscal Year: 2013
    ..This caring approach will enhance engagement and retention in care and promote movement toward personal self-advocacy and quality of life. ..
  8. The Antidepressant Action of Ketamine:Brain Chemistry
    MATE ISTVAN MILAK; Fiscal Year: 2013
    ..To study this we designed a randomized, placebo-controlled, double- blind study with several different doses of ketamine. ..
  9. Scaling up services for people with psychosis in Nigeria: a pilot study
    Oyewusi Gureje; Fiscal Year: 2012
    ..g., primary care physicians, nurses, and community health workers) working in partnership with the available psychiatric specialists, to create a program that will deliver services in community based settings [60,64,65]. ..
  10. Parameters that govern initiation of VSG switching in T.brucei
    F Nina Papavasiliou; Fiscal Year: 2013
    ..The work we propose aims to understand the mechanism of T. brucei surface coat switching, which is the sole cause of pathogen persistence and chronic infection. ..
  11. Assaying the Anthelmintic Potential of a Novel Flatworm-Specific GPCR Family
    Timothy A Day; Fiscal Year: 2013
    ....
  12. RNA CAPPING IN TRYPANOSOMES
    Christian Tschudi; Fiscal Year: 2012
    ..Unless treated, African sleeping sickness is always fatal;no vaccine has been approved and there is a very limited arsenal of drugs with generally severe shortcomings, such as high toxicity and emerging resistance. ..
  13. Building Research Capacity to Improve Mental Health in China across the Lifespan
    Arthur M Kleinman; Fiscal Year: 2013
    ..The overall goal is to develop a sustainable program of research and research training in each institution, linking research to the development of innovative mental health services for China and the region. ..
  14. Technology Diffusion &Cost-Effectiveness of Mammography Screening in Older Women
    Ya Chen Tina Shih; Fiscal Year: 2012
    ....
  15. Enhancing the Effectiveness of Physical Therapy in People with Knee OA
    G Kelley Fitzgerald; Fiscal Year: 2013
    ..These beneficial effects could have a profound impact on reducing the cost of care to society and to the person with knee OA, a major cause of disability and health care cost in the United States. ..
  16. Cost-Effectiveness of Hormonal Therapy for Clinically Localized Prostate Cancer
    STEPHEN K contact VAN DEN EEDEN; Fiscal Year: 2010
    ....
  17. Telemedicine Management of Veterans with Chronic Insomnia and PTSD
    Samuel T Kuna; Fiscal Year: 2013
    ..This would significantly increase access to treatment, particularly for Veterans residing in remote and rural settings, and decrease treatment-related costs. ..
  18. Mechanisms Underlying Stress-Induced Activation of Serotonergic Systems
    Christopher A Lowry; Fiscal Year: 2012
    ....
  19. Disability-adjusted Life Years (DALYs)
    Jurgen Rehm; Fiscal Year: 2010
    ..abstract_text> ..
  20. Genome-wide association studies of prematurity and its complications
    Jeffrey C Murray; Fiscal Year: 2010
    ....
  21. PROMISS - Prostate Modeling to Identify Surveillance Strategies
    David F Penson; Fiscal Year: 2013
    ..abstract_text> ..
  22. 1/2-An Environmental and Occupational Health Research and Training Hub: USA
    Leonelo E Bautista; Fiscal Year: 2013
    ..The proposed GEOHealth hub closely matches current Colombian environmental goals and would generate the knowledge and training needed to achieve informed, science-based environmental health decision-making. ..
  23. Quit IT: Development of a Web-based 3D Coping Skills Game to Increase Self-Effic
    HERBERT PAYSON SNOW; Fiscal Year: 2013
    ..This concept is highly marketable to a broad target audience of hospitalized smokers and may offer numerous benefits as an adjunct to current cessation interventions. ..
  24. Lithium's Molecular Mechanism of Action and the Pathology of Bipolar Disorders
    Ramin V Parsey; Fiscal Year: 2013
    ..Ultimately this can lead to novel therapeutics that are better tolerated. We will independently advance our understanding of the molecular pathophysiology of BPD as well as characterize the mechanisms of action of lithium. ..
  25. War Violence and Global Burden of Diseases Related To Substance Use and Disorders
    BRADLEY TOWNSEND KERRIDGE; Fiscal Year: 2012
    ....
  26. Tailored Hospital-based Risk Reduction to Impede Vascular Events after Stroke (TH
    Bruce Ovbiagele; Fiscal Year: 2013
    ..If successful, the strategy could serve as a ready model to be adapted by decision-makers in other under-resourced areas for lessening the burden of stroke (and other major public health challenges). ..
  27. Depression Screening RCT in ACS patients: Quality of Life and Cost Outcomes
    Karina W Davidson; Fiscal Year: 2013
    ..Health-related quality of life, depressive symptoms, and costs will be obtained from all patients, so that the benefits and the costs of these three different depression screening strategies can be compared. ..
  28. Development of a Convenient, Automated, Objective Measure of Depression
    James C Mundt; Fiscal Year: 2010
    ..Establishing a valid, noninvasive, easily obtained, and generalizable biomarker of depression severity and treatment response will contribute to better understanding of depression and development of effective treatments. ..
  29. Clinical and genetic studies of hereditary neurological disorders in Mali
    Guida Landoure; Fiscal Year: 2013
    ..This study will also train physicians and students in the characterization of neurodegenerative diseases as well as in genetic technology and molecular biology, and build a suitable research environment that will retain them. ..
  30. Web-based CBT for Substance Misusing and PTSD Symptomatic OEF/OIF Veterans
    ANDREW BRUCE ROSENBLUM; Fiscal Year: 2013
    ..ratios will be estimated to identify the incremental costs of the web-based intervention per increased quality adjusted life years (QALYs) and increased abstinence...
  31. e-MBC for Major Depressive Disorder
    JOHN BROOKS MORROW; Fiscal Year: 2012
    ..If results are promising, the next critical steps for us would be to conduct a multicenter three-arm randomized controlled trial to compare the effectiveness of e-MBC, office-based MBC, and telephone nurse follow-up. ..
  32. Health and Economic Aspects of Ocular Disease in the US
    David J Lee; Fiscal Year: 2010
    ....
  33. Locomotion in Parasitic Nematodes
    RICHARD WALTER KOMUNIECKI; Fiscal Year: 2012
    ....
  34. Fixation using Alternative Implants for the Treatment of Hip Fractures: A Multi-c
    Marc F Swiontkowski; Fiscal Year: 2012
    ..We will independently adjudicate revision surgery rates at regular intervals up to 2 years. This trial will not only change current orthopaedic practice, but will set a benchmark for the conduct of future orthopaedic trials. ..
  35. Cost effectiveness of spinal manipulative therapy for seniors with neck pain
    Brent Leininger; Fiscal Year: 2013
    ..Bronfort and co-sponsors (Drs. Evans and McDonough). NWHSU and the University of Minnesota are well suited for the applicant's training and include a CAM focused clinical research center and an NIH affiliated CTSA (1UL1RR033183). ..
  36. Locomotion in Parasitic Nematodes
    RICHARD WALTER KOMUNIECKI; Fiscal Year: 2013
    ..These studies will identify a wealth of potential novel molecular targets for drug discovery. ..
  37. Abdominal Colpopexy: Comparison of Endoscopic Surgical Strategies (ACCESS)
    ELIZABETH ROSE MUELLER; Fiscal Year: 2010
    ..A cost- effectiveness analysis will be performed that measures both costs and quality adjusted life years (QALYs) for each treatment arm...
  38. Collaborative Studies on the Genetics of Alcoholism/COGA
    Bernice Porjesz; Fiscal Year: 2013
    ..Understanding how genetic variations affect the risk for alcoholism will make important contributions to prevention and treatment of this serious disease...
  39. Community-Based VCT: Thailand
    David D Celentano; Fiscal Year: 2010
    ..Aim 2 will be evaluated by comparing a variety of behavioral measures at baseline and post intervention. Aim 3 will be evaluated in terms of cost per HIV infection averted and disability-adjusted life years (DALYs) saved. ..
  40. Community-Based HIV VCT: South Africa
    Thomas J Coates; Fiscal Year: 2010
    ..Aim 2 will be evaluated by comparing a variety of behavioral measures at baseline and post intervention. Aim 3 will be evaluated in terms of cost per HIV infection averted and disability-adjusted life years (DALYs) saved. ..
  41. ANALYSIS OF THE TRYPANOSOMA BRUCEI GENOME USING TILING ARRAYS
    Christian Tschudi; Fiscal Year: 2009
    ..Unless treated, African sleeping sickness is always fatal;no vaccine has been approved and there is a very limited arsenal of drugs with generally severe shortcomings, such as high toxicity and emerging resistance. ..
  42. Cost Effectiveness of Anticoagulation Versus Genetic Testing of CYP2C9 & VKORC1 G
    Anna Teschemaker; Fiscal Year: 2009
    ..Main and Secondary Outcomes: Cost-effectiveness, measured in dollars per quality adjusted life years gained ($/QALY) will be calculated;and the incremental cost effectiveness ratio will be measured...
  43. Process Development on a Schistosomiasis Vaccine, SchistoShield???
    Afzal A Siddiqui; Fiscal Year: 2013
    ..Funding this application will help our continuing efforts to develop Sm-p80 towards manufacture for future human clinical trials, ultimately resulting in an approved vaccine. ..
  44. Prospective Study of Air Pollution and Psychiatric Disorders
    Marc G Weisskopf; Fiscal Year: 2013
    ..Thus, we have relevant data within a very large, US-wide cohort of elderly women with which to address the novel hypothesis that long-term exposure to air pollution is related to psychiatric disorders. ..
  45. GENETIC PREDISPOSITION TESTING IN COLORECTAL CANCER
    Deborah Schrag; Fiscal Year: 2003
    ..abstract_text> ..
  46. Internet CBT for Depression: Comparing Pure, Guided, and Stepped Care
    Gregory N Clarke; Fiscal Year: 2013
    ..Finally, in this reapplication we have added a non-research Reach Estimation Phase to better estimate acceptance and retention rates under conditions that closely match real-world dissemination. ..
  47. Regulation of mRNA Turnover in Trypanosomes
    Vivian Bellofatto; Fiscal Year: 2003
    ..We have recently developed a cell-free system that is competent for both of these enzymatic activities. This work is a key first step in our proposed experimental plan. ..
  48. Community Choirs to Promote Healthy Aging and Independence of Older Adults
    Julene K Johnson; Fiscal Year: 2013
    ..the start- up and ongoing program costs for senior centers, including cost/person served and determine quality adjusted life years. If successful, results from this RCT may help develop and further the premise that creative arts can ..
  49. STATISTICAL INFERENCE FOR COST-EFFECTIVENESS ANALYSIS
    Joseph Gardiner; Fiscal Year: 2002
    ....
  50. COST-EFFECTIVENESS ANALYSIS OF SURGERY IN EPILEPSY-CEASE
    John Langfitt; Fiscal Year: 2001
    ..Benefits will be calculated by summing quality adjusted life years(QALYs), using health state utilities as quality weights...
  51. Functional genomics of metacyclogenesis in T.cruzi
    Gregory Buck; Fiscal Year: 2006
    ..In Specific Aim #4, we will use our regulatable T. cruzi genetic system and RNAi to establish the functions and roles of the differentially expressed genes that play a probable ..
  52. Enhanced Single-Visit Cervical Cancer Screening Program
    Hoda Anton Culver; Fiscal Year: 2007
    ..The incremental net cost associated with an incremental improvement in outcomes in terms of quality-adjusted life years (QALYs) will be measured. [unreadable] [unreadable]..
  53. MAJOR DEPRESSION, ANXIETY, AND LUNG TRANSPLANTATION
    Mary Amanda Dew; Fiscal Year: 2003
    ..An ultimate aim of the analyses is to refine hypotheses about the predictive sequence of effects under investigation and thereby to revise the study's conceptual model for subsequent intervention efforts. ..
  54. Global Health Comparative Effectiveness: A data synthesis method applied to HIV
    JAMES GUSTAVE KAHN; Fiscal Year: 2010
    ..The analysis will provide valuable information and tools to inform global HIV policies and programs. ..
  55. First Regional Conference on Injury and Safety Promotion - Eastern Mediterranean
    Jon Mark Hirshon; Fiscal Year: 2009
    ..This is particularly true in the Eastern Mediterranean Region. However, all too often occupational injuries are overlooked when examining injuries and injury prevention. ..
  56. Organ Replacement Technology Analysis Project (ORTAP)
    James Stahl; Fiscal Year: 2006
    ..The research will lay the groundwork for future R01 proposals by the candidate...
  57. Internet-based Self-Management Intervention for Prolonged Grief
    Brett T Litz; Fiscal Year: 2010
    ..functional impairment, physical and mental health morbidity, lost productivity, suicide, and lowered quality adjusted life years. At present, there are no evidence-based, secondary prevention interventions for PGD...
  58. Developmental Epidemiology of Co-Occurring Alcohol Use Disorders and Depression
    JAMES CRANFORD; Fiscal Year: 2009
    ....
  59. CPP Management Information Feedback and Nursing
    Catherine Kirkness; Fiscal Year: 2007
    ..across the life span for children, adolescents and adults monitored for CPP; 4) Estimate the value, in quality adjusted life years (QALY) for varying outcomes of care across the life span for children, adolescents and adults monitored ..
  60. Societal & Patient Utilities for Drug Problems
    Kevin Kraemer; Fiscal Year: 2005
    ..abstract_text> ..
  61. Patient & Societal Utilities for Alcohol Problems
    Kevin Kraemer; Fiscal Year: 2007
    ..abstract_text> ..